An open label,randomised study to evaluate the efficacy and safety of dual-therapy [lopinavir and ritonavir plus lamivudine in Chinese ART-naïve HIV-infected patients

Trial Profile

An open label,randomised study to evaluate the efficacy and safety of dual-therapy [lopinavir and ritonavir plus lamivudine in Chinese ART-naïve HIV-infected patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Lamivudine (Primary) ; Lopinavir/ritonavir (Primary) ; Efavirenz; Tenofovir
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Sep 2017 New trial record
    • 26 Jul 2017 Primary endpoint (Proportions of the patients with plasma HIV-RNA 50 copies/mL at week 48) has been met , as per results presented at the 9th International AIDS Society Conference on HIV Science.
    • 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top